Metastatic breast cancer subtypes and central nervous system metastases

Breast

Volumn 23, Issue 5, 2014, Pages 623-628

  Aversa, C ^a,b   Rossi, V ^a   Geuna, E ^a,b   Martinello, R ^a,b   Milani, A ^a,b   Redana, S ^a   Valabrega, G ^a,b   Aglietta, M ^a,b   Montemurro, F ^a,b  

^a Fondazione del Piemonte per l'Oncologia   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

BC subtypes; Brain metastases; Breast neoplasms; Survival outcome

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; TUMOR MARKER;

ARTICLE; BREAST METASTASIS; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; FATALITY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROTEIN DETERMINATION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE; SYNDROME DELINEATION; ADULT; AGED; BREAST TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; FOLLOW UP; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84908202523     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.06.009     Document Type: Article

References (34)

1. DiStefano A., Yong Yap Y., Hortobagyi G.N., Blumenschein G.R. The natural history of breast cancer patients with brain metastases. Cancer 1979, 44:1913-1918.
2. Barnholtz-Sloan J.S., Sloan A.E., Davis F.G., Vigneau F.D., Lai P., Sawaya R.E. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. JClin Oncol 2004, 22:2865-2872.
3. Tsukada Y., Fouad A., Pickren J.W., Lane W.W. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983, 52:2349-2354.
4. Lin N.U., Winer E.P. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007, 13:1648-1655.
5. Dawood S., Broglio K., Esteva F.J., Ibrahim N.K., Kau S.W., Islam R., et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008, 19:1242-1248.
6. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
7. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
8. Kennecke H., Yerushalmi R., Woods R., Cheang M.C., Voduc D., Speers C.H., et al. Metastatic behavior of breast cancer subtypes. JClin Oncol 2010, 28:3271-3277.
9. Altundag K., Bondy M.L., Mirza N.Q., Kau S.W., Broglio K., Hortobagyi G.N., et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 2007, 110:2640-2647.
10. Evans A.J., James J.J., Cornford E.J., Chan S.Y., Burrell H.C., Pinder S.E., et al. Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol R Coll Radiol 2004, 16:345-349.
11. Hicks D.G., Short S.M., Prescott N.L., Tarr S.M., Coleman K.A., Yoder B.J., et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006, 30:1097-1104.
12. Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thurlimann B., et al. Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 2013, 2013(24):2206-2223.
13. Anders C.K., Deal A.M., Miller C.R., Khorram C., Meng H., Burrows E., et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 2011, 117:1602-1611.
14. Arslan U.Y., Oksuzoglu B., Aksoy S., Harputluoglu H., Turker I., Ozisik Y., et al. Breast cancer subtypes and outcomes of central nervous system metastases. Breast 2011, 20:562-567.
15. Berghoff A., Bago-Horvath Z., De Vries C., Dubsky P., Pluschnig U., Rudas M., et al. Brain metastases free survival differs between breast cancer subtypes. Br J Cancer 2012, 106:440-446.
16. Kaplan M.A., Isikdogan A., Koca D., Kucukoner M., Gumusay O., Yildiz R., et al. Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology). Oncology 2012, 83:141-150.
17. Kwon H.C., Oh S.Y., Kim S.H., Lee S., Kwon K.A., Choi Y.J., et al. Clinical outcomes and breast cancer subtypes in patients with brain metastases. Onkologie 2010, 33:146-152.
18. Metro G., Foglietta J., Russillo M., Stocchi L., Vidiri A., Giannarelli D., et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011, 22:625-630.
19. Bartsch R., Rottenfusser A., Wenzel C., Dieckmann K., Pluschnig U., Altorjai G., et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. JNeurooncol 2007, 85:311-317.
20. Brufsky A.M., Mayer M., Rugo H.S., Kaufman P.A., Tan-Chiu E., Tripathy D., et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 2011, 17:4834-4843.
21. Church D.N., Modgil R., Guglani S., Bahl A., Hopkins K., Braybrooke J.P., et al. Extended survival in women with brain metastases from HER2 overexpressing breast cancer. Am J Clin Oncol 2008, 31:250-254.
22. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
23. Vaz-Luis I., Ottesen R.A., Hughes M.E., Marcom P.K., Moy B., Rugo H.S., et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res 2012, 14:R129.
24. Montemurro F., Di C.S., Arpino G. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann Oncol 2013, 24:2715-2724.
25. Wolff A.C., Hammond M.E., Hicks D.G., Dowsett M., McShane L.M., Allison K.H., et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. JClin Oncol 2013, 31:3997-4013.
26. Cheang M.C., Chia S.K., Voduc D., Gao D., Leung S., Snider J., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. JNatl Cancer Inst 2009, 101:736-750.
27. Aurilio G., Disalvatore D., Pruneri G., Bagnardi V., Viale G., Curigliano G., et al. Ameta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer 2014, 50:277-289.
28. Bachmann C., Grischke E.M., Fehm T., Staebler A., Schittenhelm J., Wallwiener D. CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary. JCancer Res Clin Oncol 2013, 139:551-556.
29. Duchnowska R., Dziadziuszko R., Trojanowski T., Mandat T., Och W., Czartoryska-Arlukowicz B., et al. Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Res 2012, 14:R119.
30. Braccini A.L., Azria D., Thezenas S., Romieu G., Ferrero J.M., Jacot W. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies. Breast 2013, 22:993-998.
31. Sperduto P.W., Kased N., Roberge D., Xu Z., Shanley R., Luo X., et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 2012, 82:2111-2117.
32. Hu G., Kang Y., Wang X.F. From breast to the brain: unraveling the puzzle of metastasis organotropism. JMol Cell Biol 2009, 1:3-5.
33. Bos P.D., Zhang X.H., Nadal C., Shu W., Gomis R.R., Nguyen D.X., et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459:1005-1009.
34. Pestalozzi B.C. Brain metastases and subtypes of breast cancer. Ann Oncol 2009, 20:803-805.